Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib ...

CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage ...

Companies will discuss how Lantern’s AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate’s lead investigational drug product, elraglusib CHICAGO ...

Companies will discuss how Lantern's AI platform is being leveraged for the identification and development of enrichment biomarkers for Actuate's lead investigational drug product, elraglusib CHICAGO ...

The company is investing in enhancing the AI capabilities of its MicroStrategy ONE analytics platform. In 2023, the company expanded a multiyear partnership with Microsoft to integrate ...